are observed clinically and experimentally during extrahepatic cholestasis (2) (3) (4) (5) .
We have produced a monoclonal antibody (HAM.4) against a membrane glycoprotein of normal rat hepatocytes (6) . HAM.4 antigen has been found to be present predominantly on the bile canalicular membrane of hepatocytes and on the luminal surface of bile ducts. The identification and physiological function of HAM.4 antigen are unknown. The aims of the present study were to compare the serum profile of HAM.4 antigen to those of bile canalicular enzymes during extrahepatic cholestasis and to purify this antigen from liver and determine its molecular weight.
MATERIALS AND METHODS
Experimental Model. Male Sprague-Dawley rats (Clea Japan Inc., Tokyo, Japan) weighing approximately 300 g were used in this study. The rats had free access to water, were fed ad libitum, and housed in a constant tempera-ture and humidity environment with alternating 12-hr light and dark cycles. All surgical procedures were conducted under ether anesthesia. The common bile duct was doubly ligated immediately distal to its origin and dissected between the two ligatures, through a midline abdominal incision. The rats were allowed food and water ad libitum after the operation. At various times after bile duct ligation, groups of six rats were anesthetized with ether and exsanguinated by heart puncture. Some animals were given cycloheximide (1 mg/kg body weight, intramuscularly) 1 hr before bile duct ligation (4) . Additional groups of four rats served as sham-operated controls. The sera were stored at -20°C. A small piece of liver was taken from each animal for immunohistochemicaI examination. Normal bile was collected via a cannula (PE-50 tubing, Clay Adams, Parsipanny, New Jersey) inserted into the common bile ducts of ether-anesthetized untreated rats. The experimental protocols observed the National Research Council's criteria for the care and use of laboratory animals in research.
Preparation of Monoclonal Antibody HAM.4. A murine monoclonal antibody against a membrane glycoprotein of normal rat hepatocytes (HAM.4) was produced as described previously (6) .
Measurement of HAM.4 Antigen in Serum. The level of HAM.4 antigen was determined as described previously (6) . In brief, serum samples were incubated with a known amount of HAM.4, and the amount of unbound HAM.4 remaining in the incubation mixture was then determined using hepatocytes as a target and radioactively labeled anti-mouse IgG antibody as a detector system. Seventyfive microliters of HAM.4 diluted 1:2000 with 0.5% bovine serum albumin in phosphate-buffered saline (BSA-PBS) was mixed with an equal volume of the serum sample and left overnight at 4°C to allow HAM.4 to bind to the antigen in the sample. Duplicate 50-~1 aliquots were then incubated for 1 hr at 4°C with an equal volume of glutaraldehyde-fixed hepatocytes (1 × 106 cells per assay) suspended in 0.5% BSA-PBS: the rat hepatocytes were obtained by collagenase digestion as described previously (7) . After this incubation, the cells were washed three times with 0.1% BSA-PBS (200g for 5 min), and then 50 i~1 of 125I-labeled sheep F(ab')2 anti-mouse IgG (2 p.Ci/ml in 0.1% BSA-PBS; New England Nuclear) was added in a second similar incubation. Finally, the cells were washed three times as described above, and the radioactivity bound to the cells was counted The nonspecific binding was determined by omitting HAM.4 from the assay. All of the samples tested for Figure 1 (below) were analyzed using a single batch of glutaraldehyde-fixed hepatocytes.
Biochemical Assays. ALP, LAP, ~/-GTP, and glutamicpyruvic transaminase (GPT) activities, and total bilirubin concentration in serum were assayed by automated systems using clinical methods (SRL, Tokyo, Japan). DPP-IV activity in serum was determined using a commercial test kit (GP-DAP TEST) obtained from Fuji Revio Inc. (Tokyo, Japan) according to the procedure provided by the manufacturer.
Preparation of Monoclonal Antibody .Affinity Column.
The monoclonal antibody HAM.4 was purified from mouse ascites fluid using a commercial kit (Monoclonal Antibody Purification kit II; Bio-Rad Laboratories, Richmond, California). The purified HAM.4 was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) at a ratio of 5 mg protein/ml swollen gel.
Purification of HAM.4 Antigen. A crude membrane fraction from rat liver cells was prepared following the method described previously (8) . Briefly, the liver was homogenized with 0.5% Tween 40 in PBS. A crude cell membrane fraction was prepared by centrifugation. The membrane fraction was solubilized in 2% sodium deoxycholate (DOC) in 10 mM Tris HCI buffer, pH 8.0. Affinity chromatography was performed by the method described previously (8) . The deoxycholate extract of liver cell membrane was passed through the affinity column equilibrated with 0.5% DOC in 10 mM Tris HCI buffer, pH 8.0. The column was washed with 0.5% DOC in 10 mM Tris HCI buffer, pH 8.0, and eluted with 0.5% DOC in 0.05 M diethylamine, pH 11.5. To determine the molecular weight of HAM.4 antigen in normal bile or in serum collected from cholestatic rats, the HAM.4 antigen in the bile or serum was concentrated using the immunoaffinity column as described above.
Gel Electrophoresis. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out by the method of Laemmli (9) using a 7.5% polyacrylamide gel, and the gels were stained with Coomassie blue. Molecular weight standard proteins were obtained from Sigma Chemical Company (St. Louis, Missouri).
Western Blotting. Following electrophoresis, blotting to nitrocellulose filter membrane was performed according to the method of Towbin et al (10) . The blots were blocked using nonfat dried milk and subsequently treated with HAM.4 (1:5000 dilution). The blots were developed with the Amersham blotting detection kit for mouse immunoglobulins (Amersham, UK).
Morphological and Immunohistochemicai Studies. Sections of the liver were fixed with periodate-lysineparaformaldehyde using the method of McLean and Nakane (11) , and embedded in paraffin wax. Indirect immunoperoxidase staining was performed by the method described previously (12) . Briefly, the deparaffinized sections were incubated with HAM.4 and developed with horseradish peroxidase-conjugated F(ab')2 fragments of rabbit anti-mouse IgG (Zymed Laboratories Inc., San Francisco, California) and 3, sections were counterstained with methyl green. Sections of the same specimens were also stained with hematoxylin-eosin. Statistics. Data are presented as means _ SEM. Significance was considered to be P < 0.05. Statistical analyses were performed using Duncan's multiple range test and Student's t test.
RESULTS

Effect of Bile Duct Ligation on Serum HAM.4
Antigen. Figure 1 shows the level of HAM.4 antigen in serum after bile duct ligation. The amount of serum HAM.4 antigen was increased within 1 hr after bile duct ligation, and reached a maximum (two times that in sham-operated rats) at 3 hr. It gradually decreased thereafter until 48 hr, where it plateaued. The level of serum HAM.4 antigen in ligated rats was significantly higher than that in sham-operated rats at all points after the operation (P < 0.01). Cycloheximide administration did not change the serum levels of HAM.4 antigen observed 3 hr after ligation (data not shown).
Effect of Bile Duct Ligation on Serum Enzymes and Total Bilirubin. As shown in Figure 2 , serum ALP, LAP, DPP-IV, and GPT activities were significantly elevated at 6, 48, 3, and 2 hr, respectively, and reached their maximum levels at 24, 72, 12, and 24 hr after bile duct ligation, respectively. Serum 7-GTP activity was significantly increased by 24 hr and did not reach a maximum until 168 hr after the operation. Serum total bilirubin concentration was significantly increased by 6 hr and reached a maximum at 96 hr after ligation. None of the serum profiles for these enzymes or bilirubin coincided with that of HAM.4 antigen. The activities of these serum enzymes and bilirubin did not change significantly in sham-operated rats.
Molecular Weight of HAM.4 Antigen. Liverderived HAM.4 antigen purified by immunoaffinity chromatography showed a single major band with a molecular weight of 110 kDa when analyzed by SDS-PAGE ( Figure 3, lane 2) . As shown in Figure  4 , a band with the same molecular weight was detected when western blots of liver cell membrane preparation or immunopurified HAM.4 antigen were immunostained using HAM.4 and a biotinylated anti-mouse immunoglobulin antibody. The molecular weight of HAM.4 antigen in normal bile and in serum of cholestatic rats was also 110 kDa ( Figure 4, lane 3, lane 4) .
Morphological and Immunohistoehemical Findings. The main histological feature was the progressive increase in cholangiolar proliferation in the duct ligation in rats, and the serum profile differs from those for the biliary marker enzymes, ALP, LAP, ~-GTP, and DPP-IV activities. Serum levels of HAM.4 antigen are significantly increased earlier than the levels of serum bilirubin or the activities of the four biliary marker enzymes in this model. The kinetics of the well-known biliary marker enzymes during extrahepatic cholestasis in this study are comparable with the results reported previously (4, 5) . HAM.4 antigen was purified from rat liver using immunoaffinity chromatography and had a molecular weight of 110 kDa by SDS-PAGE and western blotting. These results suggest that HAM.4 antigen may be a potential marker for the early stage of extrahepatic cholestasis. A variety of surface antigens of the sinusoidal, lateral, and canalicular membranes of rat hepatocytes have been characterized by immunohistochemical techniques using monoclonal antibodies (6, (12) (13) (14) (15) (16) (17) (18) . Some of these antigens have also been identified biochemically (8, 13) . However, little is known about the levels of these plasmalemmal antigens in serum. One previous study has detected a biliary cell membrane glycoprotein with a molecular weight of 150 kDa in the serum of cholangiocarcinoma-bearing rats by immunoprecipitation (18) . In this report, we measured an increase in the serum levels of HAM.4 antigen during cholestasis in rats using a binding inhibition assay.
HAM.4 antigen and DPP-IV have very similar molecular weights and subcellular localizations in the liver (19) . In addition, the monoclonal antibody HAM.4 was found to immunoprecipitate DPP-IV in a preliminary study (Kobayashi, unpublished observation). Therefore, it is possible that a part of the increase in the serum concentration of HAM.4 antigen may be explained by this cross-reaction. However, DPP-IV activity in serum reached its peak at 12 hr, compared to 3 hr for HAM.4 antigen levels. Therefore, it is still uncertain whether HAM.4 an- tigen is identical to DPP-IV, because the possibility remains that HAM.4 may only cross-react with DPP-IV. Information regarding the protein sequence of HAM.4 antigen will be required to definitively answer this question.
The present studies do not give sufficient information to explain the mechanism(s) whereby the HAM.4 antigen reaches the serum. Possible mechanisms for the elevation of serum levels of HAM.4 antigen and other canalicular proteins include increased biosynthesis, regurgitation, or changes in cellular trafficking. Since cycloheximide did not inhibit the increase in serum HAM.4 antigen at 3 hr after bile duct ligation, the early steep rise of the antigen in serum does not seem to require an increase in biosynthesis of the antigen. Regurgitation of HAM.4 antigen from the bile tract to the blood could occur by paracellular (20) (21) (22) and/or transcellular pathways (23, 24) . It has been demonstrated that obstruction of the bile duct disrupts tight junctions between adjoining hepatocytes and bile duct cells (20) (21) (22) , which may allow paracellular movement of bile into blood. However, it seems unlikely that this tight junction permeability is responsible for the very rapid rise in serum HAM.4 antigen because it is reported that damage to tight junctions takes a much longer time to develop (20) (21) (22) . Cholestasis could also change the cellular trafficking of HAM.4 antigen, resulting in the misdirected delivery of, or redistribution of, this protein. In bile ductligated rats, it has been demonstrated that there is a subcellular redistribution of alkaline phosphatase (25) (26) (27) , canalicular bile salt transport protein (28) , and B10 antigen (15) from the canalicular to the basolateral membrane. If a similar process occurs for HAM.4 antigen, then increased antigen levels at the basolateral membrane might facilitate the release of this protein into the blood. One further possibility is that HAM.4 antigen preexisting in the sinusoidal domain of hepatocytes could be released into the blood, since a small amount of HAM.4 antigen was recently detected in the sinusoidal membrane using immunoelectron microscopic localization (29) . Although the present immunohistochemical studies did not show any noticeable changes in the amount or distribution of HAM.4 antigen in the liver after bile duct ligation, the amount of antigen released into the blood is probably small and, therefore, changes in hepatic levels may be difficult to detect with the immunohistochemical technique used.
The results of the present study suggest that HAM.4 antigen may be useful as a potential marker to analyze the very early stage of cholestasis, although further studies are necessary to elucidate the identity of this protein and the mechanism(s) of its release into the blood. 
